Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lori Sax"'
Autor:
Nedal Bukhari, Andrea Marie Ibrahim, Lori Sax, Michael M. Vickers, Christina Canil, Sandeep Sehdev, Kim Koczka, Kylea Potvin, Michael Ong, D. Scott Ernst, M. Neil Reaume, Eric Winquist, James Vanhie
Publikováno v:
Journal of Clinical Oncology. 36:193-193
193 Background: Outcomes of patients (pts) undergoing CHT for mHSPC are heterogeneous, with some rapidly developing castration-resistance (CRPC). While AVPC ("anaplastic") features are described in CRPC, less is known in the mHSPC setting. In this mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a2d8827f4644f188978bcab8620ecbb
https://doi.org/10.1200/jco.2018.36.6_suppl.193
https://doi.org/10.1200/jco.2018.36.6_suppl.193
Publikováno v:
Journal of Clinical Oncology. 35:260-260
260 Background: The addition of docetaxel to standard androgen deprivation therapy (ADT) has been shown to improve the survival of men with metastatic hormone-sensitive prostate cancer (MHSPC) (Sweeney 2015, James 2016). We noticed PSA progression in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da5454d4f522e8ffd819ca8c7c312eb4
https://doi.org/10.1200/jco.2017.35.6_suppl.260
https://doi.org/10.1200/jco.2017.35.6_suppl.260
Publikováno v:
Journal of Clinical Oncology. 28:5593-5593
5593 Background: Aprepitant is an NK-1 antagonist that reduces delayed nausea and vomiting (N&V) in pts receiving high-dose (HD) cisplatin. Single-agent HD cisplatin 100 mg/m2 iv q3weeks × 3 doses ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67d5341d221a8ff00216f63e2003959a
https://doi.org/10.1200/jco.2010.28.15_suppl.5593
https://doi.org/10.1200/jco.2010.28.15_suppl.5593